Clinical trial
Combination Chemotherapy Plus PSC 833 Followed by Interleukin-2 in Treating…
NCT00002925 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00002925 |
|---|---|
| Title | Combination Chemotherapy Plus PSC 833 Followed by Interleukin-2 in Treating Patients With Acute Myelogenous Leukemia |
| Official title | Phase I Study of MDR Modulation With PSC-833 (NSC# 648265) With a Pilot Study of Cytogenetic Risk-Adapted Consolidation Followed by a Phase II Pilot Study of Immunotherapy With RIL-2 (NSC # 373364) in Previously Untreated Patients With AML< 60 Years |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Leukemia |
| Intervention type | Biological, Drug |
| Interventions | ara-C, Daunorubicin, Etoposide, PSC-833, Aldesleukin |
| Enrollment | 410 |
| Start date | Feb 1, 1997 |
| Primary completion | Nov 1, 2003 |
| Completion | Jun 1, 2010 |
| First posted | Jul 19, 2004 |
| Last update posted | Nov 30, 2012 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: